The U.S. Food and Drug Administration (FDA) has reportedly accused biotechnology firm uniQure of presenting distorted and manipulated clinical data regarding its AMT-130 drug. Following these allegations, the law firm Hagens Berman announced an update to its ongoing securities class action investigation against the company. Federal officials issued a public rebuke, characterizing the AMT-130 product as a failure despite the company's previous representations to the market. The accusations suggest a significant breach of scientific integrity and potential efforts to mislead investors about the drug's true efficacy. This development poses a severe threat to uniQure’s market valuation and future regulatory prospects, as investor trust faces a sharp decline. Legal pressure continues to mount as shareholders seek accountability for the alleged misconduct.
Sign up free to access this content
Create Free Account